Arvest Bank Trust Division Sells 1,808 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Arvest Bank Trust Division cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 87,145 shares of the medical research company's stock after selling 1,808 shares during the period. IQVIA makes up approximately 1.0% of Arvest Bank Trust Division's investment portfolio, making the stock its 29th largest position. Arvest Bank Trust Division's holdings in IQVIA were worth $17,125,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares in the last quarter. Geode Capital Management LLC raised its position in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after purchasing an additional 77,981 shares in the last quarter. Invesco Ltd. increased its stake in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after buying an additional 59,426 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Up 1.2 %

IQV stock traded up $1.69 during trading on Tuesday, reaching $142.91. The stock had a trading volume of 656,973 shares, compared to its average volume of 1,408,081. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company's 50 day moving average is $175.30 and its two-hundred day moving average is $195.79. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $25.20 billion, a price-to-earnings ratio of 19.06, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the topic of several research reports. Robert W. Baird decreased their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Truist Financial cut their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, Mizuho reduced their target price on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.